To investigate the need to biopsy erythematous lesions of the bladder after bacille Calmette-Gu erin (BCG) treatment as well as the diagnostic value of voided urine cytology in the detection of recurrence.
Introduction
Intravesical BCG immunotherapy is the standard adjuvant therapy for intermediate-and high-risk non-muscle-invasive bladder cancer (NMIBC) and carcinoma in situ [1] . Forty years after its introduction, BCG treatment remains the most effective agent against NMIBC in terms of preventing recurrence [2] [3] [4] [5] . Furthermore, BCG treatment applied with 1-3 years of maintenance therapy is the only treatment regimen associated with a lower progression risk compared with transurethral resection of bladder tumour (TURBT) alone or TURBT combined with other instillation therapies [6, 7] ; however,~33-44% of patients receiving BCG may experience recurrence or progression, and some will require radical cystectomy [4, 8] . Regular cystoscopy surveillance is therefore mandatory. Although frequent analysis of voided urine cytology, together with cystoscopy, is recommended by European Association of Urology (EAU) guidelines for intermediate-and high-risk NMIBC, the value of voided urine cytology is not uniformly accepted among clinicians [1] . The reported median sensitivity and specificity for cytology to detect any kind of urothelial cancer after treatment of primary NMIBC are 35% (13-75%) and 94% (85-100%), respectively, indicating that cytology is poor as a negative predictor but quite good as positive predictor in the detection of recurrent urothelial cancer [9] .
While BCG instillations are effective in preventing recurrences, 40-51% of patients experience local side effects such as cystitis, haematuria and urinary frequency [10] . Local side effects often coincide with concomitant erythematous bladder lesions, which are difficult to distinguish from carcinoma in situ or flat tumour confined to the mucosa. Given the controversy regarding the diagnostic significance of urine cytology, the management of erythematous lesions of BCG-treated bladder is heterogeneous. During BCG instillations, erythematous lesions probably signify bladder irritation and in the presence of negative cytology biopsy is not needed [11, 12] ; however, occurrence of erythema and other bladder lesions is common during later follow-up after a BCG regimen. The objectives of the present study were to classify the cystoscopic appearance of BCG-induced bladder mucosal lesions during post-BCG surveillance and to correlate cystoscopy findings with urine cytology and subsequent histological assessment.
Patients and Methods

Study Participants and Identification
After receiving institutional ethical review board approval, 206 consecutive patients with primary NMIBC treated with BCG in 2009-2015 were identified at one central hospital and one academic tertiary care centre. The clinical and histopathological data for each biopsy or TURBT specimen taken after initialization of BCG treatment were included in the study and analysed individually.
The BCG treatment comprised an induction course of 6-week BCG instillations followed by maintenance therapy up to a maximum of 2 years. During the study period, two maintenance regimens were used: monthly instillations and the maintenance regimen according to the protocol provided by the Southwest Oncology Group (SWOG) [13] . Patients were assigned to follow-up according to the EAU guideline principles, with outpatient clinic cystoscopies and voided urine cytology evaluation. If an obvious recurrent tumour was observed, TURBT was performed under general or spinal anaesthesia. If small or unclear lesions were detected, either outpatient clinic biopsy or TURBT under anaesthesia was performed. There was no standard practice to retrieve random biopsies from normal-appearing bladder. Photodynamic diagnosis was used at the judgement of the treating urologist. The majority (78.5%) of biopsies or TURBTs were performed under white-light cystoscopy.
Description of the Lesion According to Cystoscopic Findings
Suspicious bladder lesions were categorized according to their appearance as follows: papillary tumours: tumours highly suspicious for urothelial cancer with papillary growth pattern rising from mucosa; flat tumours: sessile tumours or suspicious tissue confined to mucosa including those described as velvet-like growth; erythemas: erythematous patches of bladder with no tumour rising from mucosa; and normal cystoscopy: randomly biopsied specimens.
Histopathological Categorization of the Lesion
The histopathology of the biopsy was categorized as benign if normal mucosa or non-malignant process (i.e. inflammation, granulomatous inflammation, hyperplasia, metaplasia, granulation tissue or scar tissue) was diagnosed and malignant if recurrence or progression of urothelial carcinoma was diagnosed.
Voided Urine Cytology
Voided urine cytology was reported according to the Papanicolaou classification system (i.e. class 1: normal urothelial cells; class 2: atypical, non-malignant urothelial cells; class 3: slight suspicion of malignancy; class 4: clear suspicion of malignancy; class 5: malignant cytology), combined with the pathologist's description of cytological atypia for classes 2-5 [14] . Neither of the hospitals used the Paris system for reporting urine cytology during the study period [15] . Cytology was categorized as negative if cell morphology appeared normal, or if non-specific inflammatory changes or mild atypia was found (Papanicolaou class 1 or 2). Any suspicion or evidence of malignancy was categorized as positive (Papanicolaou class 3, 4 or 5). Urine cytology was correlated with the histopathology of the subsequent biopsy taken.
Statistical Analysis
All biopsies and TURBT histology samples were analysed as individual events. Urine cytology, cystoscopy appearance of biopsy target, histopathological data and time point in post-BCG surveillance were taken into account. Data on biopsies with missing cytology were excluded from the calculations. The sensitivity, specificity, negative predictive value (NPV) and positive predictive value (PPV) for cytology to detect malignancy were calculated for each lesion category to identify the prognostic value of lesion appearance in combination with the cytology. IBM SPSS Statistics, version 24.0.0.1 (IBM Corp., Armonk, NY, USA) and JMP Pro 12.2.0 (SAS Institute Inc., Cary, NC, USA) were used for statistical analysis.
Results
The clinicopathological characteristics of the study populations are presented in Table 1 . The patients had a median age of 73 years, 180 (87%) were men and 27 (13%) women. Primary NMIBC staging was Ta in 135 (56%) cases, T1 in 49 (24%) cases, and carcinoma in situ in 22 (11%) cases. All patients were classified in intermediate-or high-risk groups (26% and 74%, respectively) according to the European Organization for the Research and Treatment of Cancer (EORTC) risk tables [16] . None of the patients in the study population was classified in the low risk group. The median amount of BCG instillations given was 14, which corresponds to~9-10 months of treatment duration.
The characteristics of biopsy targets are reported in Table 2 . During surveillance (median follow-up time 35 months) after BCG instillation, 159 patients (76%) underwent one or more biopsies or tumour resections (overall 448 biopsies or tumour resections). Urine cytology was available for 367 biopsies. The most common biopsy target was erythematous lesion (57% of all biopsies). Altogether, 209 erythematous lesions were biopsied, of which 187 (89.5%) were found to be benign, representing either non-specific inflammation or granulomatous inflammation. Cytology was in line with the biopsy result in 156 (75%) biopsies of erythematous lesions. Nine biopsies were diagnosed as malignant with negative cytology and 13 with positive cytology.
The diagnostic accuracy of cytology to detect malignancy is reported in Table 3 . Correlated to the histological findings, the overall sensitivity, specificity, NPV and PPV for cytology to detect malignancy were 39%, 77%, 69% and 48%, respectively. In the case of papillary tumours, the sensitivity, specificity, NPV and PPV were 32%, 86%, 26% and 89%, respectively. Flat tumours showed values similar to papillary tumours with sensitivity, specificity, NPV and PPV of 37%, 83%, 34% and 85%. Cytology was found most accurate if erythema only was detected; the sensitivity, specificity, NPV and PPV were 59%, 76%, 94% and 23%, respectively. Among random biopsies from normal-appearing mucosa, the sensitivity, specificity, NPV and PPV were 100%, 63%, 100% and 25%, respectively. Table 4 shows the histopathological T-category of the 22 malignancies found from erythematous lesions. Of the nine biopsies diagnosed as malignant with negative cytology, six were stage Ta, two T1 and one carcinoma in situ. With positive cytology present, two muscle-invasive tumours, eight carcinoma in situ lesions, one T1 stage and two Ta tumours were found. Figure 1 shows the occurrence of erythematous lesions during follow-up in 3-month periods. Erythematous lesions were most frequently detected during the first 9 months, which correlates with the median duration of the BCG course (~9-10 months). As a result, after 9 months from the beginning of BCG treatment, the occurrence of erythematous lesions gradually reduced. After 2 years of surveillance, the occurrence of erythema was significantly lower, although such lesions were detected up to 84 months after the first instillation. Malignant histology, however, was detected equally often during the both periods before and after 2 years 
Discussion
Suspicious bladder lesions are frequently encountered during follow-up of patients with previous BCG instillations.
Papillary or flat morphology is highly suggestive of tumour recurrence, and tumour resection should be undertaken regardless of cytology grade; however, more than half of bladder lesions after BCG present as erythematous patches, which raises the question of how these frequently encountered, benign-appearing bladder changes should be dealt with. Diagnostic options include the following: biopsy or TURBT under general anaesthesia; cold cup biopsy in an outpatient setting; and surveillance. Cytology had a PPV of 23% and an NPV of 94% among patients with erythematous bladder changes, suggesting that biopsy or TURBT is indicated when cytology is positive but is not routinely needed if cytology is negative. Erythematous bladder changes should not be overlooked as >10% may harbour significant malignancy, including muscle-invasive tumours and stage T1 Prevalence is the percentage of malignancies diagnosed from each lesion category; NPV, negative predictive value; PPV, positive predictive value. The present study suggests that urine cytology is best at predicting malignancy if erythematous bladder changes are seen, whereas, in the case of papillary or flat tumours, cytology adds limited value. In fact, the present study is consistent with the view that cytology has poor or no diagnostic value in the management of papillary or flat tumours detected by cystoscopy. Macroscopic tumours should always be removed by TURBT regardless of cytology. The added value of photodynamic diagnosis in detecting malignancy in erythematous or other lesion types cannot be estimated because photodynamic diagnosis was applied according to the judgement of the treating urologists in a minority (21.5%) of selected patients.
Several studies have investigated the need for routine bladder biopsy after an induction course of BCG to confirm the treatment response before proceeding to maintenance therapy. It has been established that erythematous lesions are benign in nature in the presence of negative cytology at the time of 3-6 months from the first instillation of BCG. A retrospective study and cumulative analysis by Swietek et al. [12] estimated the predictive value of individual lesion type in cystoscopy performed after an induction course of BCG. The authors found that the PPV of erythema with positive cytology was 56% and 9% with negative cytology present. Cumulative analysis included six studies yielding PPV of erythema with positive and negative cytology of 59% and 9%, respectively [11, [17] [18] [19] [20] [21] . Results suggest that routine biopsy is not needed after the induction course of BCG if erythematous or normal mucosa is seen and cytology is negative.
In the present study, we analysed all biopsies taken during the whole course of post-BCG surveillance with a median follow-up time of~3 years. Our results show that erythematous lesions are frequently encountered during BCG treatment and~1 year after the end of treatment; however, erythematous lesions are also encountered after several months after BCG treatment (up to 84 months). During surveillance, malignancy may be more easily suspected if BCG has not been given in several months and erythematous lesions appear. Our results show that the proportion of malignancies found in erythematous lesions is the same during the BCG course as later during surveillance, which suggests that the diagnostic strategy discussed earlier is safe during the whole course of post-BCG surveillance.
A sensitivity of 35% (13-75%) for cytology to detect urothelial cancer recurrence has been reported, which is in line with findings of the present study; however, the overall specificity of 77% for cytology in the present series is notably lower than the previously reported overall specificity median of 94% (85-100%) [9] . Discrepancy among studies estimating the sensitivity and specificity of cytology may be accounted for by factors such as the cytology being undertaken for primary diagnostics or as part of surveillance, different patient characteristics and interobserver variability, which may also have influenced the present results [9, 22, 23] . Furthermore, BCG treatment as topical bladder immunotherapy may impair the cytological assessment by causing enlargement of the nuclei, hyperchromasia and distortion of the nuclearcytoplasmic ratio also in benign urothelial cells [24] . This may also have hampered the evaluation of cytology and increased the proportion of positive cytology results, thus lowering the specificity because the majority of erythematous lesions were found to be benign.
The present study has some limitations including its retrospective design and the limited number of patients. The appearance of each lesion, which was the most essential study variable, was re-analysed and categorized based on the initial assessment described in the cystoscopy report. As it was not possible to re-review the cystoscopy findings, the inclusion and exclusion criteria for each lesion category may harbour a source of bias. In addition, we did not re-review the histopathology of cytology nor the biopsy specimens; however, all cystoscopies and TURBTs were performed by experienced urologists, and pathological specimens were analysed by dedicated cytologists and pathologists.
In conclusion, the present study describes the histopathological natural history of post-BCG lesions. The study shows that papillary and flat tumours should always be removed by TURBT regardless of cytology grade. Erythematous lesions were benign in 90% of cases throughout the post-BCG surveillance, although we emphasize their clinical significance because some of them may harbour significant malignancies. Positive cytology therefore warrants further examination including a biopsy of erythematous lesions whenever detected. Most unnecessary biopsies of erythematous lesions can be avoided based on urine cytology, and routine biopsy is not recommended if erythema is detected with negative cytology present.
